Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LumibirdLTS:0FRI 80 Cash Ratio is 0.70 as of Dec. 2025, which is 4% below its 10-year median of 0.73. GuruFocus rates LTS:0FRI with a GF Score™ of 80/100 and a GF Value™ of €16.66 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 207 Medical Diagnostics & Research companies, Lumibird ranks worse than 59.9% on this metric.
Lumibird has a Cash Ratio of 0.70. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Lumibird's Cash Ratio or its related term are showing as below:
LTS:0FRI'
s Cash Ratio Range Over the Past 10 Years
Min: 0.39 Med: 0.73 Max: 1.68
Current: 0.7
During the past 13 years, Lumibird's highest Cash Ratio was 1.68. The lowest was 0.39. And the median was 0.73.
LTS:0FRI's Cash Ratio is ranked worse than 59.9% of 207
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.99
vs LTS:0FRI: 0.70
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Lumibird Cash Ratio Related Terms
Lumibird Cash Ratio Historical Data
* Premium members only.
The historical data trend for Lumibird's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Lumibird's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumibird Cash Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lumibird's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Lumibird's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumibird (LTS:0FRI) has a Cash Ratio of 0.70 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lumibird and its competitors. This is near median its historical median of 0.73. Over the past decade, Lumibird's Cash Ratio has ranged from 0.39 to 1.68. According to the industry distribution chart, Lumibird ranks #124 out of 207 companies in the Medical Diagnostics & Research industry, placing it in the top 59.9%.
Is Lumibird's Cash Ratio too high?
Lumibird's current Cash Ratio of 0.70 is near median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 1.68. The Medical Diagnostics & Research industry median Cash Ratio is 0.99. Lumibird's value of 0.70 is 29.3% below this industry median. Based on the distribution chart, Lumibird ranks #124 out of 207 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lumibird has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumibird's Cash Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumibird ranks #124 out of 207 companies for Cash Ratio. This places Lumibird in the lower half of its industry. The industry median Cash Ratio is 0.99. Lumibird's value of 0.70 is 29.3% below this benchmark. Historically, Lumibird's own Cash Ratio has ranged from 0.39 to 1.68 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 0.99, Lumibird has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Diagnostics & Research company?
The median Cash Ratio among Medical Diagnostics & Research companies is 0.99, based on 207 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumibird's current Cash Ratio of 0.70 is 29.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lumibird and its competitors. For the Medical Diagnostics & Research industry, the median Cash Ratio is 0.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumibird's current Cash Ratio is 0.70, which is near median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumibird stock overvalued right now?
Based on GuruFocus' analysis, Lumibird (LTS:0FRI) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.66, compared to a current price of €26.90 — trading 61.5% above its estimated fair value. The current Cash Ratio is 0.70, which is near median its 10-year median of 0.73 and 29.3% below the Medical Diagnostics & Research industry median of 0.99. Lumibird's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Lumibird (LTS:0FRI), the current Cash Ratio is 0.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumibird (LTS:0FRI) Overvalued in 2026?
Based on GuruFocus' analysis, Lumibird stock appears to be overvalued.
The current stock price of €26.90 is trading 61.5% above its estimated GF Value™ of €16.66.
GuruFocus considers Lumibird to be Significantly Overvalued.
Key valuation signals for LTS:0FRI:
Cash Ratio: 0.70 (near median its 10-year median of 0.73)
GF Value™: €16.66 vs. price of €26.90 (61.5% above fair value)
Industry Position: 29.3% below the Medical Diagnostics & Research median (#124 of 207)
No single metric tells the full story. See the LTS:0FRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications.
80GF Score
Get the complete analysis for LTS:0FRI
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0FRI has been successfully added to your 
